Last updated: August 8, 2025
Introduction
VISIPAQUE 270, a widely used iodinated contrast agent, plays a critical role in diagnostic imaging, particularly computed tomography (CT) scans. Developed by GE Healthcare, this contrast media enhances vascular and tissue visualization, aiding in precise medical diagnoses. Given its importance, understanding the global supply landscape, key suppliers, and manufacturing dynamics is vital for healthcare providers, procurement professionals, and industry stakeholders aiming for supply security and cost efficiency.
Overview of VISIPAQUE 270
VISIPAQUE 270 contains iohexol, a non-ionic, water-soluble iodine compound, administered intravenously. It is valued for its high diagnostic efficacy, lower adverse reaction profile compared to older ionic agents, and broad clinical applications. Its 270 mg/mL iodine concentration is standard for many diagnostic procedures.
Global Manufacturing and Supply Chain
Manufacturing of VISIPAQUE 270 primarily involves large pharmaceutical and biotech companies with specialized aseptic production facilities. The supply chain spans raw material procurement, formulation, sterile filling, quality control, packaging, and distribution. Ensuring a stable supply of quality raw materials, such as iodine and excipients, is crucial for uninterrupted production.
Key Suppliers and Manufacturers
-
GE Healthcare
As the originator and primary supplier of VISIPAQUE 270, GE Healthcare maintains production facilities predominantly in Europe, the United States, and Asia. The company's extensive global distribution network ensures availability across regions. GE Healthcare continuously optimizes its manufacturing processes and supply chain resilience to meet global demand.
-
Contract Manufacturing Organizations (CMOs)
In response to increasing demand and supply chain complexities, GE Healthcare often collaborates with CMOs specializing in sterile pharmaceutical manufacturing. These partnerships help scale production capacity and diversify geographical supply sources.
-
Raw Material Suppliers
The production of iohexol and related excipients relies on a network of raw material suppliers worldwide. Key raw materials include iodine derivatives, solvents, and stabilizers. Leading chemical manufacturers such as LANXESS, from whom high-purity iodine derivatives are procured, are integral to the supply chain.
-
Regional Distributors and Authorized Resellers
Regional distributors and authorized resellers are crucial for local distribution, especially in emerging markets. They facilitate faster delivery, regulatory compliance, and inventory management.
Market Dynamics and Supply Challenges
- Global Demand Fluctuations: An aging population and rising prevalence of diagnostic imaging procedures increase demand for VISIPAQUE 270, exerting pressure on supply chains.
- Regulatory Approvals and Compliance: Stringent regulations in different countries influence manufacturing practices and licensing. Ensuring compliance with FDA, EMA, and other regulatory standards is essential for market access.
- Supply Disruptions: Pandemic-related disruptions, geopolitical tensions, and raw material shortages can impact manufacturing efficiency and delivery timelines.
- Competition and Alternatives: While GE Healthcare dominates, alternative contrast agents, both ionic and non-ionic, compete in the market, influencing supply dynamics and pricing.
Emerging Trends and Supply Outlook
- Manufacturing Investments: GE Healthcare and other stakeholders are investing in expanded production capacity and new facilities to mitigate supply challenges.
- Supply Chain Digitization: Adoption of advanced inventory management, real-time monitoring, and predictive analytics enhances supply chain robustness.
- Regional Manufacturing Hubs: Establishment of regional production units aims to reduce lead times and foster localized supply resilience.
Conclusion
The primary supplier of VISIPAQUE 270 is GE Healthcare, leveraging a sophisticated global manufacturing and distribution network. The supply landscape benefits from collaborations with CMOs, raw material suppliers, and regional distributors. However, factors such as demand growth, regulatory demands, raw material availability, and geopolitical challenges continue to influence supply stability. Stakeholders should monitor these trends closely and foster diversified sourcing strategies to ensure consistent availability of this vital diagnostic contrast agent.
Key Takeaways
- GE Healthcare is the principal global supplier of VISIPAQUE 270, supported by a broad network of manufacturing partners and regional distributors.
- Supply chain resilience relies on diversified raw material sources, regional production hubs, and strategic partnerships.
- Increasing demand for diagnostic imaging drives the need for capacity expansion and logistical optimization, avoiding shortages.
- Regulatory compliance remains critical; manufacturers must navigate complex approvals across jurisdictions to maintain market access.
- Monitoring geopolitical and macroeconomic trends is essential for anticipating potential disruptions and proactively managing supply risks.
FAQs
1. Who are the main manufacturers of VISIPAQUE 270?
GE Healthcare is the primary manufacturer of VISIPAQUE 270 globally, with additional production support from contract manufacturing organizations to meet rising demand.
2. Are there alternative suppliers or similar contrast agents in the market?
While GE Healthcare dominates, other companies like Bayer and Bracco offer iodinated contrast agents, including Omnipaque and Ultravist, respectively. However, they differ in formulation and iodine concentration.
3. What supply challenges could impact VISIPAQUE 270 availability?
Factors include raw material shortages (notably high-purity iodine), manufacturing capacity constraints, regulatory delays, geopolitical tensions, and increased global demand.
4. How does GE Healthcare ensure the quality and safety of VISIPAQUE 270?
Through rigorous quality control protocols, adherence to Good Manufacturing Practices (GMP), and compliance with regulatory standards across jurisdictions.
5. What trends are shaping the future supply landscape for VISIPAQUE 270?
Investments in new manufacturing facilities, adoption of digital supply chain technologies, regional production hubs, and strategic raw material sourcing are key trends aimed at enhancing supply security.
References
[1] GE Healthcare. (2022). "VISIPAQUE (Iohexol) Product Details."
[2] European Medicines Agency. (2021). "Regulatory Status of Iodinated Contrast Media."
[3] Market Research Reports. (2022). "Global Contrast Media Market Overview."
[4] Iodine Derivatives Suppliers. (2021). "Supply Chain Analysis for Medical Iodine."
